

Memorial Sloan Kettering Cancer Center
is pleased to announce:

Practical Management Strategies and New Innovations in Prostate Radiotherapy



*Featuring World Renowned
Speakers Covering
Cutting-Edge Topics*

Thursday-Friday
December 8-9, 2016

**CALL FOR
ABSTRACTS**

Conference Location:

Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street New York, NY 10065



Memorial Sloan Kettering
Cancer Center



Course Overview

The course will include coverage of the following topics:

- Comparing outcomes for surgery and radiotherapy in clinically localized disease
- Optimal management strategies to treat acute and late side effects of radiotherapy
- Tips for reducing errors and improving QA for Prostate Brachytherapy
- Updates on SBRT and Proton therapy in the treatment of Prostate Cancer
- Salvage radiotherapy after primary treatment failures and Expected Toxicity Outcomes
- Optimal Integration of Hormonal therapy with Prostate Radiotherapy
- New Developments in External Beam Treatment Planning including MR-Treatment Planning
- Guidelines for the Radiation Oncologist contouring Target and Nodal Regions
- Integrating imaging into Treatment Selection and Treatment Planning

TARGET AUDIENCE

The target audience includes Radiation Oncologists, Urologists, Medical Oncologists, Medical Physicists, Radiation Therapists, Nurses and Residents.


Course Faculty

MSK COURSE DIRECTOR




Michael J. Zelefsky MD
Vice Chair, Department of Radiation Oncology, Clinical Research; Chief, Brachytherapy Service

MSK CO-COURSE DIRECTOR



Marisa A. Kollmeier MD
Radiation Oncologist, Attending



Sean McBride MD MPH
Radiation Oncologist, Attending

MSK FACULTY

Oguz Akin MD
Radiologist

Stefan Both PhD
Dept. of Medical Physics

Oren Cahlon MD
Radiation Oncologist
Director, Proton Therapy

Gilad Cohen MS
Senior Radiotherapy Physicist

Jonathan Coleman MD
Urologist

James Eastham MD FACS
Surgeon; Chief, Urology Service; Florence and Theodore Baumritter/Enid Ancell Chair of Urologic Oncology

Richard M. Gewanter MD
Radiation Oncologist
Chief, Commack/Rockville Center Radiation Oncology

Laura Happersett MS
Radiotherapy Physicist, Sr., Dept of Medical Physics

Margie A. Hunt MS
Chief, Clinical Physics Service

Philip Kantoff MD
Medical Oncologist
Chair, Department of Medicine; George J. Bosl Chair

James G. Mechalakos PhD
Section Head of External Beam Treatment, Dept. of Medical Physics

Michael J. Morris MD
Medical Oncologist

John P. Mulhall MD
Director, Male Sexual and Reproductive Medicine Program

Simon N. Powell MD PhD FRCP
Radiation Oncologist
Chair, Department of Radiation Oncology; Enid A. Haupt Chair in Radiation Oncology

Jaspreet S. Sandhu MD
Urologic Surgeon

Susan F. Slovin MD PhD
Medical Oncologist

Neelam Tyagi PhD
Assistant Attending P-hysicist, Dept of Medical Physics

Herbert Alberto Vargas MD
Radiologist

Wolfgang A. Weber MD
Nuclear Medicine Physician
Chief, Molecular Imaging and Therapy Service

INVITED FACULTY

Kristy Brock-Leatherman PhD
Associate Professor, Nuclear Engineering & Radiological Sciences; Associate Professor, Radiation Oncology; Associate Professor, Biomedical Engineering, University of Michigan

Juanita Crook MD
Radiation Oncologist, BC Cancer Foundation Agency

Anthony Victor D'Amico MD PhD
Professor, Radiation Oncology, Harvard Medical School; Chief, Genitourinary Radiation Oncology, Brigham And Women's Hospital; Chief, Genitourinary Radiation Oncology, Dana-Farber Cancer Institute

Mark Emberton MD FRCS Urol
Dean, Faculty of Medical Sciences, University College London

Steven Jay Frank MD
Associate Professor, Dept of Radiation Oncology, MD Anderson Cancer Center

Carri Glide-Hurst PhD
Senior Staff Physicist, Henry Ford Hospital

Carlo Greco MD
Director of Clinical Research, Champalimaud Centre for the Unknown, Lisbon, Portugal

Peter Hoskin MD
Consultant Clinical Oncologist, East and North Hertfordshire NHS Trust

Patrick McLaughlin MD
Medical Oncologist, University of Michigan

Jeff Michalski MD MBA
Professor, Radiation Oncology; Vice Chairman, Radiation Oncology; Chief, Genitourinary Service, Washington University in St. Louis

Allan Pollack MD PhD
Professor and Chairman of Radiation Oncology, University of Miami

Mack Roach MD
Professor & Chair, Department of Radiation Oncology, and Professor, Department of Urology, University of California, San Francisco

Howard Sandler MD MS
Chair, Radiation Oncology, Cedars-Sinai Medical Center

Matthew Smith MD PhD
Professor, Medicine, Harvard Medical School; Assistant in Medicine, Hematology/Oncology, Massachusetts General Hospital

Robert Timmerman MD
Professor, Radiation Oncology, Neurological Surgery, University of Texas, Southwestern

Anthony Laurence Zietman MD
Associate Director, Harvard Radiation Oncology Residency Program; Director, GU Service, Massachusetts General Hospital

CALL FOR ABSTRACTS

Participants are invited to submit an abstract for presentation at the meeting. Abstracts for the poster session will be selected on the basis of their scientific merit and content quality. **The deadline for abstract submissions is 9/15/16.** Visit the conference website for more information:
www.mskcc.org/radiotherapy.

Thursday, December 8, 2016

7:00-7:50 am	BREAKFAST & REGISTRATION	3:15-4:15 pm	Structure Contouring: Basic Anatomy and What's New? MODERATOR Sean McBride MD, MPH
7:50-8:00 am	Welcome & Introduction Michael J. Zelefsky MD		<ul style="list-style-type: none">MRI Anatomy of the Prostate and Critical Normal Tissues Patrick McLaughlin MDContouring Normal Tissue Structures with Confidence - Contouring the Pelvic nodes with confidence Oguz Akin MDMulti-modality Image Registration and Fusion: Evaluating uncertainty and building confidence Kristy Brock-Leatherman PhDPanel Discussion and Q&A
8:00-9:15 am	SESSION A: Comparative Outcomes and Toxicity Management Comparison of Outcomes and Toxicities and QOL between Treatment Interventions MODERATOR Marisa A. Kollmeier MD <ul style="list-style-type: none">Comparison of Surgery and Radiotherapy for High Risk Disease: The Urologist's Perspective James Eastham MD, FACSComparison of Surgery, EBRT and Brachytherapy Based Modalities for High Risk Disease - The Radiation Oncologist Perspective Mack Roach MDComparison of Toxicity and QOL Outcomes between Surgery and Radiotherapeutic Interventions Jeff Michalski MD, MBAPanel Discussion - Q&A	4:15-4:30 pm	COFFEE BREAK
		4:30-6:00 pm	Advances in External Beam Treatment Planning and Delivery MODERATOR Neelam Tyagi PhD <ul style="list-style-type: none">Guidelines for Target and Normal Tissue Dose Constraints for EBRT and SBRT Laura Happersett MSRefining the State-of-the-Art: Simulation through Treatment Planning: What are the New Treatment Planning Programs Able to Accomplish? James G. Mechalakos PhDAdvances in Multi-Modality Image-Based Planning and MR-Based Simulation Carri Glide-Hurst PhDTreatment Delivery: Novel Approaches to Motion Reduction and Image Guidance Margie A. Hunt MSPanel Discussion and Q&A
9:15-10:30 am	Optimal Use of Androgen Deprivation Therapy (ADT) and Radiotherapy MODERATOR Sean McBride MD, MPH <ul style="list-style-type: none">Optimal Duration of ADT for Intermediate and High Risk Disease Anthony Victor D'Amico MD, PhDManaging the Side Effects of Prolonged ADT? Susan Slovin MD PhDMaintaining Bone Health for the Patient Treated with ADT Matthew Smith MD, PhDPanel Discussion and Q&A	6:00-6:45 pm	Cocktail Reception & Poster Presentations
10:30-11:00 am	COFFEE BREAK		
11:00-12:00 pm	Optimizing Management of Side Effects after EBRT and Brachytherapy MODERATOR Michael J. Zelefsky MD <ul style="list-style-type: none">Addressing GI Toxicity Marisa A. Kollmeier MDAddressing GU Toxicity Jaspreet S. Sandhu MDAddressing Sexual Dysfunction John Mulhall MDPanel Discussion and Q&A		
	SESSION B: Radiotherapy Treatment Interventions: Technical Aspects		
12:00-1:00 pm	Imaging for Prostate Cancer- Impact on Staging and Treatment Selection MODERATOR Richard M. Gewanter MD <ul style="list-style-type: none">MP-MRI: Opportunities to Assess and Predict Treatment Response Herbert Alberto Vargas MDMolecular Imaging and Novel Tracers in Prostate Cancer Wolfgang A. Weber MDPutting It All Together: Using Imaging to Inform Treatment Options Steven Jay Frank MDPanel Discussion and Q&A	7:30-8:00 am	BREAKFAST
		8:00-9:00 am	Department of Medicine Grand Rounds Biomarkers and Genomics for Prostate Cancer Philip Kantoff MD
			SESSION C: Novel Radiotherapy Treatment Interventions: Clinical Aspects
		9:15 10:30 am	SBRT Outcomes and Advances MODERATOR Michael J. Zelefsky MD <ul style="list-style-type: none">Tumor Control Outcomes and Toxicity for SBRT Michael J. Zelefsky MDModerate Hypofractionation Allan Pollack MD, PhDHigh Dose Fractionated SBRT Robert Timmerman MDSingle Dose Radiotherapy for Localized Disease Carlo Greco MDPanel Discussion and Q&A
1:00-2:00 pm	LUNCH BREAK	10:30-10:45 am	COFFEE BREAK
2:00-3:15 pm	Brachytherapy: Indications, Tumor Control Outcomes and Toxicity and Advances in the OR MODERATOR Marisa Kollmeier MD <ul style="list-style-type: none">LDR-Indications, Relative Contraindications, and Where Are We in 2016 Juanita Crook MDHDR Indications, Relative Contraindications, and Where Are We in 2016 Peter Hoskin MDAdvances in the Operating Room: Real Time Treatment Assessments and Imaged Based Fusions for Dose Intensification Michael J. Zelefsky MDOptimal QA in the OR- Reducing Errors Gilad Cohen MSPanel Discussion and Q&A		

TO REGISTER TODAY, PLEASE VISIT:

www.mskcc.org/Radiotherapy



10:45-11:45 am

Proton Therapy: Is there an Established Role in the Treatment of Localized Disease?

MODERATOR Oren Cahlon MS

- **Clinical Outcomes & Toxicity and Tolerance Profiles and Comparison to Photon IMRT**
Anthony Laurence Zietman MD
- **Treatment Planning Challenges**
Stefan Both PhD
- **Cost Effectiveness of Protons versus Other Radiotherapeutic Interventions- Is there a Winner?**
Steven Jay Frank MD
- **Panel Discussion and Q&A**

11:45-1:00 pm

Improving Our Radiotherapy Outcomes for Intermediate and High Risk Prostate Cancer

MODERATOR Anthony Laurence Zietman MD

- **Important Considerations for Optimizing Outcomes for Local & Regional Therapy Using Radiotherapy in Intermediate and High Risk Disease**
Marisa A. Kollmeier MD
- **Elective Lymph Node Irradiation for Prostate Cancer: When, How and Is it Worth it?**
Mack Roach MD
- **Ongoing and Protocols in the Works for Prostate Cancer**
Howard Sandler MD, MS
- **Strategies Incorporating Targeted Therapy and Novel Anti-androgen and Radiotherapy**
Sean McBride MD, MPH
- **Panel Discussion and Q&A**

1:00-1:45 pm

LUNCH BREAK

SESSION D:

Salvage Therapy after Primary Treatment Failure

1:45-2:45 pm

Salvage Radiotherapy after Surgery

MODERATOR Howard Sandler MD, MS

- **Salvage versus Adjuvant Radiotherapy following Radical Prostatectomy**
Anthony Victor Damico MD, PhD
- **Optimal Contouring and Treatment planning considerations in the Salvage Setting**
Allan Pollack MD PhD
- **The Role of Hormonal Therapy in the Salvage Setting**
Anthony Laurence Zietman MD
- **Panel Discussion and Q&A**

2:45-3:45 pm

Salvage Options after RT failure

MODERATOR Michael J. Zelefsky MD

- **Outcomes with Brachytherapy as Salvage for Radio-Recurrent Disease**
Marisa A. Kollmeier MD
- **Outcomes of Surgery and Other Approaches in the Salvage Setting**
Jonathan Coleman MD
- **Focal Therapy Options and Outcomes**
Mark Emberton MD FRCS Urol
- **Panel Discussion and Q&A**

3:45 pm

ADJOURN

Registration

REGISTRATION FEES	EARLY Before 10/8/16	GENERAL After 10/8/16
MDs, PhDs, DOs, and Medical Physicists	\$400	\$500
MSK Alliance and MSK Alumni	\$280	\$350
Residents, Fellows, RNs, Medical Students and other Healthcare Providers	\$150	\$250
Industry Members*	\$875	\$875

*Industry Members: Registration is for educational purposes only. Marketing, sales, and promotion of products and services are prohibited at CME activities.

TO REGISTER TODAY, PLEASE VISIT:

www.mskcc.org/Radiotherapy

Registration includes continental breakfast, lunch, and refreshment breaks. Please contact us at least one week prior to the course if you have any special dietary needs.

Registration is complimentary for MSK staff who wish to attend this course. However, you must register online by visiting the Continuing Medical Education page on **OneMSK**.

CONTACT Continuing Medical Education
Memorial Sloan Kettering Cancer Center
633 Third Avenue, 12th Floor New York, New York 10017
cme@mskcc.org

COURSE DESIGN

This course includes hands-on review of cases which will be intermixed with short didactic lectures.

EVALUATION

A course evaluation survey sent out electronically will provide attendees with the opportunity to review the sessions and the speakers and to identify future educational needs.

OUTCOMES MEASUREMENT SURVEY

Six months after the end of the course an Outcomes Measurement Survey will be sent to all participants to help us determine what positive impacts have been made on participant practice as a result of the course.

ACCREDITATION STATEMENT

MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT


MSK designates this live activity for a maximum of **15.5 AMA PRA Category 1 Credits™**. Physicians should only claim credit commensurate with the extent of their participation in the activity. The AMA has determined that physicians not licensed in the United States but who participate in this CME activity are eligible for **15.5 AMA PRA Category 1 Credit(s)™**.

FACULTY DISCLOSURE

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it sponsors as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity sponsored by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

ACCOMMODATIONS

For information on hotels in the area of MSKCC with discounted rates, please visit: www.mskcc.org/accommodations.



Memorial Sloan Kettering
Cancer Center

CONTINUING MEDICAL EDUCATION
633 Third Avenue, 12th Floor
New York, New York 10017

Practical Management Strategies and New Innovations in Prostate Radiotherapy

December 8-9, 2016

www.mskcc.org/Radiotherapy